ReviewAging and disease2021
Super-Refractory Status Epilepticus: Prognosis and Recent Advances in Management.
Review in Aging and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Surgical management of status epilepticus: A systematic review.Epilepsia open · 2024Pooled it
- Favorable Neurological Outcome Following Prolonged Super-Refractory Status Epilepticus in a Resource-Limited Setting: A Case Report.Clinical case reports · 2026Article
- Cyclic Recurrence of Seizures as a Marker for Super-Refractory Status Epilepticus.Brain and behavior · 2026Article
- Febrile infection-related epilepsy syndrome with claustrum sign following a human rhinovirus-positive respiratory illness in an adult: a case report.Frontiers in immunology · 2026Article
- A nomogram model for predicting seizure control in status epilepticus: development and risk factor analysis.Frontiers in neurology · 2026Article
- Treating status epilepticus in clinical practice-a multi-national survey in Germany, Austria, and Switzerland.Frontiers in neurology · 2025Article
- Article
- Stopping runaway seizures with a chill pill.eLife · 2024Article
- New Pharmacological Therapies in the Treatment of Epilepsy in the Pediatric Population.Journal of clinical medicine · 2024Review
- Super-refractory status epilepticus in a woman withFrontiers in medicine · 2024Article
- Hippocampal glucocorticoid receptors modulate status epilepticus severity.Neurobiology of disease · 2023Article
- Risk factors for super-refractory and mortality in generalized convulsive status epilepticus: a 10-year retrospective cohort study.Therapeutic advances in neurological disorders · 2023Article
- Large-scale transient peri-ictal perfusion magnetic resonance imaging abnormalities detected by quantitative image analysis.Brain communications · 2023Article
- Factors associated with mortality in patients with super-refractory status epilepticus.Scientific reports · 2022Article
- Ketamine in adult super-refractory status epilepticus: Efficacy analysis on a prospective registry.Acta neurologica Scandinavica · 2022Article
- Animal Models of Epilepsy: A Phenotype-oriented Review.Aging and disease · 2022Review
- Good seizure outcome after focal resection surgery for super-refractory status epilepticus: Report of two cases.Surgical neurology international · 2022Article
- Neurological and Neurodegenerative Disorders: Novel Concepts and Treatment.Aging and disease · 2021Article
- ACVIM Consensus Statement on the management of status epilepticus and cluster seizures in dogs and cats.Journal of veterinary internal medicineArticle
- Factors affecting prognosis of status epilepticus among patients presenting to a tertiary care hospital.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Super-refractory status epilepticus (SRSE) is a life-threatening neurological emergency with high morbidity and mortality. It is defined as "status epilepticus (SE) that continues or recurs 24 hours or more after the onset of anesthesia, including those cases in which SE recurs on the reduction or withdrawal of anesthesia." This condition is resistant to normal protocols used in the treatment of status epilepticus and exposes patients to increased risks of neuronal death, neuronal injury, and disruption of neuronal networks if not treated in a timely manner. It is mainly seen in patients with severe acute onset brain injury or presentation of new-onset refractory status epilepticus (NORSE). The mortality, neurological deficits, and functional impairments are significant depending on the duration of status epilepticus and the resultant brain damage. Research is underway to find the cure for this devastating neurological condition. In this review, we will discuss the wide range of therapies used in the management of SRSE, provide suggestions regarding its treatment, and comment on future directions. The therapies evaluated include traditional and alternative anesthetic agents with antiepileptic agents. The other emerging therapies include hypothermia, steroids, immunosuppressive agents, electrical and magnetic stimulation therapies, emergent respective epilepsy surgery, the ketogenic diet, pyridoxine infusion, cerebrospinal fluid drainage, and magnesium infusion. To date, there is a lack of robust published data regarding the safety and effectiveness of various therapies, and there continues to be a need for large randomized multicenter trials comparing newer therapies to treat this refractory condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.